Omega Funds
SelectiveFiled to raiseBoston, MABiotech & pharma, Digital health, Consumer apps & internetLast fund filed April 2023
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Omega Fund VIII | April 2023 | Indefinite | $580M | 66 |
| Omega Fund VIIFiled to raise in 2021, with no closing reported yet. | 2021 | Indefinite | $0 | 0 |
| Omega Fund VIFiled to raise in 2018, with no closing reported yet. | 2018 | $400M | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Claudio Nessi | Selective | Biotech & pharma | 5 | 2 |
Categories of Omega Funds’s own portfolio companies, based on 22 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Cure Ventures | 13 | Alessa Therapeutics, Deep 6 AI, Gossamer Bio, KINSA, Loop Now Technologies, Medable, MobiSocial, PARATEK PHARMACEUTICALS, PIPER THERAPEUTICS, Rulai, Sparta Software, TRIDENT PHARMACEUTICALS, ZingBox |
| Atlas Venture | 3 | Ikena Oncology, Morphic Holding, Scorpion Therapeutics |
| 82vs | 2 | Arsanis, Avitide |
| Richard LimNot on the current fund | Slowing | Biotech & pharma, Digital health, Consumer apps & internet | 13 | 1 |
| Anne-Mari PasterNot on the current fund | Quiet | None listed | 0 | 0 |
| Francesco Draetta | Quiet | Biotech & pharma | 2 | 0 |
| Otello Stampacchia | Quiet | Biotech & pharma | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Omega Funds’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 2 |
| PARATEK PHARMACEUTICALS, Scorpion Therapeutics |
| SV Life Sciences | 2 | Arsanis, Avitide |
| Vida Ventures | 2 | Scorpion Therapeutics, Third Arc Bio |
| ARCH Venture Partners | 1 | Gossamer Bio |
| Borealis | 1 | Avitide |
| Drover Ventures | 1 | Arsanis |
| Frazier Life Sciences | 1 | Amunix Pharmaceuticals |
| FYRFLY Venture Partners | 1 | Sparta Software |
| JMI Equity | 1 | Gossamer Bio |
| Kleiner Perkins | 1 | KINSA |
| NEA | 1 | Trevi Therapeutics |
| Pillar VC | 1 | PIPER THERAPEUTICS |
A shared board seat: a company where filings name a Omega Funds partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.